EGFR lung cancer patients are missing trials they qualify for. Help us find out why.
We’re interviewing patients, caregivers, oncologists and trial sponsors to learn where the path to trials breaks down.
Healthy cell. Divides only when the body needs it.
The moment we study
One handoff decides whether a patient ever hears about a trial
For many people with EGFR-mutated lung cancer, the path looks like this. Our interviews focus on the single step where too many journeys quietly end.
Diagnosis
Testing finds an EGFR mutation, a target with real options.
First-line therapy
Targeted treatment begins, often with a strong response.
Progression
The cancer adapts and the first treatment stops working.
The handoff
Who raises trials, when, and with what information? This is what we are asking.
A matching trial
The destination exists. The question is who gets guided there.
Who we talk to
Four perspectives on the same broken path
A missed trial looks different depending on where you stand. We are listening to everyone who touches the journey, 15 minutes at a time.
Patients
People living with EGFR lung cancer: what searching for a next option actually feels like when time matters.
Caregivers
The partners and family members who research, call, and advocate. Often the real navigators of the system.
Oncologists
The clinicians making referral decisions under real time pressure, with incomplete trial information.
Trial sponsors
The teams and CROs whose studies stall waiting for eligible patients they know are out there.

Our interviews
From patient cancer diagnosis to site clinical trial recruitment.
In every conversation with patients, caregivers, oncologists and trial sponsors, we want to understand how finding the right trial works today.
Questions we ask
How does your team recruit patients for a cancer trial today?
Walk us through it, from first referral to enrollment.
Where does recruitment for cancer trials break down for your team?
And why does it break down there?
How often do you face recruitment breakdowns?
For a patient, a practice or a trial team.
Why does getting trial recruitment right matter to you?
What happens when recruitment goes wrong.
What do you do about recruitment breakdowns today?
The workarounds, tools and people you rely on.
Meet the team
The people behind BioKindred
Rooted in the EGFR patient community, with clinical-data, cancer-biology and partnership experience, and a physician advisor.

Sharon Kassa
Co-founder & CEO
Sharon worked at Deloitte on the roughly $2.5B Ethio Telecom IPO and helped raise about $11.1M for six companies through a USAID-backed program. She brings Lung Kindred, the community she founded to connect lung cancer patients and caregivers by mutation.
Education
- MA, Business Leadership
- BA, Management

Juliet Mirambo
Co-founder & CTO
Juliet is a technical lead developer and value chain manager at Merck KGaA, building systems that match clinical trial drug formulations. She brings work on antibody-drug conjugate initiatives for cancer and a forecasting model for €250M in global planning.
Education
- BS, Chemistry and Engineering

Semaria Kebede
Co-founder & Head of Go-to-Market and Partnerships
Semaria is an entrepreneur and Mandela Washington Fellow who previously built a technology business. She brings experience in growth strategy, partnerships and customer discovery to BioKindred, where she explores how cancer patients find and navigate relevant clinical trials.
Education
- MBA, University of California, Riverside

Ali Gholamian Moghaddam
Co-founder & Head of Cancer Biology
Ali is a cancer biology researcher with experience in drug discovery, molecular biology and biomarker detection. He brings research on potential anticancer compounds for lung and colorectal cancer and synthetic biosensors for biomarkers, grounding BioKindred in biomarker-driven cancer science.
Education
- PhD candidate, Biology, St. John’s University
- MS, Biology, University of Louisiana Monroe
Advisor

Dr. David Lo
Clinical Advisor
David is a practicing family medicine physician, an adjunct professor at Touro College of Osteopathic Medicine and the founder of ProMed United, an evidence-based tutoring and mentorship company for healthcare learners. At BioKindred, he advises on clinical questions.
Education
- DO, Rowan-Virtua School of Osteopathic Medicine
- MBS, Rutgers University
